U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

erlotinib response - Efficacy

MedGen UID:
1001787
•Concept ID:
CN322731
•
Sign or Symptom

Professional guidelines

PubMed

Systemic treatment and radiotherapy for patients with non-small cell lung cancer (NSCLC) and HIV infection - A systematic review.
Brandão M, Durieux V, Auprih M, Fozza A, Dauby N, Cuccia F, Aspeslagh S, Verhaert M, Giaj-Levra N
Lung Cancer 2023 Apr;178:75-86. Epub 2023 Jan 21 doi: 10.1016/j.lungcan.2023.01.010. PMID: 36806897
Drug-drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure.
Raoul JL, Moreau-Bachelard C, Gilabert M, Edeline J, Frénel JS
ESMO Open 2023 Feb;8(1):100880. Epub 2023 Feb 8 doi: 10.1016/j.esmoop.2023.100880. PMID: 36764092Free PMC Article
Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment.
Passaro A, Guerini-Rocco E, Pochesci A, Vacirca D, Spitaleri G, Catania CM, Rappa A, Barberis M, de Marinis F
Pharmacol Res 2017 Mar;117:406-415. Epub 2017 Jan 12 doi: 10.1016/j.phrs.2017.01.003. PMID: 28089942

Recent clinical studies

Etiology

EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study.
Peng P, Gong J, Zhang Y, Zhou S, Li Y, Han G, Meng R, Chen Y, Yang M, Shen Q, Chu Q, Xia S, Zhang P, Zhang L, Chen Y, Zhang L
Radiother Oncol 2023 Jul;184:109681. Epub 2023 Apr 25 doi: 10.1016/j.radonc.2023.109681. PMID: 37105304
Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma.
Xu Y, Kong W, Cao M, Wang J, Wang Z, Zheng L, Wu X, Cheng R, He W, Yang B, Dong B, Pan J, Chen Y, Huang J, Jiang C, Zhai W, Li F, Chen R, Zhou X, Wu G, Geng X, Chen J, An H, Yuan Y, Xu T, Chen D, Lin D, Xu L, Huang K, Peng L, Yu Y, Tai S, Qi H, Luo K, Kang X, Wang H, Huang Y, Zhang J, Xue W
Eur Urol 2023 Feb;83(2):163-172. Epub 2022 Jun 15 doi: 10.1016/j.eururo.2022.05.029. PMID: 35715365
Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset.
Ohe Y, Imamura F, Nogami N, Okamoto I, Kurata T, Kato T, Sugawara S, Ramalingam SS, Uchida H, Hodge R, Vowler SL, Walding A, Nakagawa K
Jpn J Clin Oncol 2019 Jan 1;49(1):29-36. doi: 10.1093/jjco/hyy179. PMID: 30508196Free PMC Article
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators
N Engl J Med 2018 Jan 11;378(2):113-125. Epub 2017 Nov 18 doi: 10.1056/NEJMoa1713137. PMID: 29151359
Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
Yang Z, Hackshaw A, Feng Q, Fu X, Zhang Y, Mao C, Tang J
Int J Cancer 2017 Jun 15;140(12):2805-2819. Epub 2017 Mar 27 doi: 10.1002/ijc.30691. PMID: 28295308

Diagnosis

EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study.
Peng P, Gong J, Zhang Y, Zhou S, Li Y, Han G, Meng R, Chen Y, Yang M, Shen Q, Chu Q, Xia S, Zhang P, Zhang L, Chen Y, Zhang L
Radiother Oncol 2023 Jul;184:109681. Epub 2023 Apr 25 doi: 10.1016/j.radonc.2023.109681. PMID: 37105304
Efficacy and safety of EGFR inhibitors and radiotherapy in locally advanced non-small-cell lung cancer: a meta-analysis.
Li X, Wang F, Jia H, Lian Z, Ren K, Yuan Z, Wang P, Zhao L
Future Oncol 2022 Sep;18(27):3055-3065. Epub 2022 Aug 10 doi: 10.2217/fon-2022-0491. PMID: 35947522
The Marine-Derived Macrolactone Mandelalide A Is an Indirect Activator of AMPK.
Mattos DR, Wan X, Serrill JD, Nguyen MH, Humphreys IR, Viollet B, Smith AB 3rd, McPhail KL, Ishmael JE
Mar Drugs 2022 Jun 27;20(7) doi: 10.3390/md20070418. PMID: 35877711Free PMC Article
The efficacy and safety of erlotinib compared with chemotherapy in previously treated NSCLC: A meta-analysis.
Wu FZ, Song JJ, Zhao ZW, Huang XF, Mao JT, Tu JF, Chen MJ, Chen WQ, Fang SJ, Zheng LY, Fan XX
Math Biosci Eng 2019 Aug 28;16(6):7921-7933. doi: 10.3934/mbe.2019398. PMID: 31698647
Bevacizumab and erlotinib versus bevacizumab for colorectal cancer treatment: systematic review and meta-analysis.
Kaveh S, Ebrahimi P, Rezapour A, Mozafari M, Sayehmiri K
Int J Clin Pharm 2019 Feb;41(1):30-41. Epub 2019 Jan 4 doi: 10.1007/s11096-018-0754-1. PMID: 30610548

Therapy

Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer.
Camidge DR, Barlesi F, Goldman JW, Morgensztern D, Heist R, Vokes E, Spira A, Angevin E, Su WC, Hong DS, Strickler JH, Motwani M, Dunbar M, Parikh A, Noon E, Blot V, Wu J, Kelly K
J Clin Oncol 2023 Feb 10;41(5):1105-1115. Epub 2022 Oct 26 doi: 10.1200/JCO.22.00739. PMID: 36288547Free PMC Article
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators
N Engl J Med 2018 Jan 11;378(2):113-125. Epub 2017 Nov 18 doi: 10.1056/NEJMoa1713137. PMID: 29151359
Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
Yang Z, Hackshaw A, Feng Q, Fu X, Zhang Y, Mao C, Tang J
Int J Cancer 2017 Jun 15;140(12):2805-2819. Epub 2017 Mar 27 doi: 10.1002/ijc.30691. PMID: 28295308
Erlotinib.
Steins M, Thomas M, Geissler M
Recent Results Cancer Res 2014;201:109-23. doi: 10.1007/978-3-642-54490-3_6. PMID: 24756788
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C
Lancet Oncol 2011 Aug;12(8):735-42. Epub 2011 Jul 23 doi: 10.1016/S1470-2045(11)70184-X. PMID: 21783417

Prognosis

Erlotinib.
Steins M, Thomas M, Geißler M
Recent Results Cancer Res 2018;211:1-17. doi: 10.1007/978-3-319-91442-8_1. PMID: 30069756
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators
N Engl J Med 2018 Jan 11;378(2):113-125. Epub 2017 Nov 18 doi: 10.1056/NEJMoa1713137. PMID: 29151359
Erlotinib.
Steins M, Thomas M, Geissler M
Recent Results Cancer Res 2014;201:109-23. doi: 10.1007/978-3-642-54490-3_6. PMID: 24756788
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, Esteban E, Molinier O, Brugger W, Melezínek I, Klingelschmitt G, Klughammer B, Giaccone G; SATURN investigators
Lancet Oncol 2010 Jun;11(6):521-9. Epub 2010 May 20 doi: 10.1016/S1470-2045(10)70112-1. PMID: 20493771
Erlotinib.
Steins M, Thomas M, Geissler M
Recent Results Cancer Res 2010;184:21-31. doi: 10.1007/978-3-642-01222-8_2. PMID: 20072828

Clinical prediction guides

EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study.
Peng P, Gong J, Zhang Y, Zhou S, Li Y, Han G, Meng R, Chen Y, Yang M, Shen Q, Chu Q, Xia S, Zhang P, Zhang L, Chen Y, Zhang L
Radiother Oncol 2023 Jul;184:109681. Epub 2023 Apr 25 doi: 10.1016/j.radonc.2023.109681. PMID: 37105304
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer.
Camidge DR, Barlesi F, Goldman JW, Morgensztern D, Heist R, Vokes E, Spira A, Angevin E, Su WC, Hong DS, Strickler JH, Motwani M, Dunbar M, Parikh A, Noon E, Blot V, Wu J, Kelly K
J Clin Oncol 2023 Feb 10;41(5):1105-1115. Epub 2022 Oct 26 doi: 10.1200/JCO.22.00739. PMID: 36288547Free PMC Article
Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma.
Xu Y, Kong W, Cao M, Wang J, Wang Z, Zheng L, Wu X, Cheng R, He W, Yang B, Dong B, Pan J, Chen Y, Huang J, Jiang C, Zhai W, Li F, Chen R, Zhou X, Wu G, Geng X, Chen J, An H, Yuan Y, Xu T, Chen D, Lin D, Xu L, Huang K, Peng L, Yu Y, Tai S, Qi H, Luo K, Kang X, Wang H, Huang Y, Zhang J, Xue W
Eur Urol 2023 Feb;83(2):163-172. Epub 2022 Jun 15 doi: 10.1016/j.eururo.2022.05.029. PMID: 35715365
Erlotinib.
Steins M, Thomas M, Geißler M
Recent Results Cancer Res 2018;211:1-17. doi: 10.1007/978-3-319-91442-8_1. PMID: 30069756
Erlotinib.
Steins M, Thomas M, Geissler M
Recent Results Cancer Res 2014;201:109-23. doi: 10.1007/978-3-642-54490-3_6. PMID: 24756788

Recent systematic reviews

Efficacy and safety of EGFR inhibitors and radiotherapy in locally advanced non-small-cell lung cancer: a meta-analysis.
Li X, Wang F, Jia H, Lian Z, Ren K, Yuan Z, Wang P, Zhao L
Future Oncol 2022 Sep;18(27):3055-3065. Epub 2022 Aug 10 doi: 10.2217/fon-2022-0491. PMID: 35947522
Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis.
Zhao Y, Liu J, Cai X, Pan Z, Liu J, Yin W, Chen H, Xie Z, Liang H, Wang W, Guo Z, Zhao S, Liang W, He J
BMJ 2019 Oct 7;367:l5460. doi: 10.1136/bmj.l5460. PMID: 31591158Free PMC Article
Bevacizumab and erlotinib versus bevacizumab for colorectal cancer treatment: systematic review and meta-analysis.
Kaveh S, Ebrahimi P, Rezapour A, Mozafari M, Sayehmiri K
Int J Clin Pharm 2019 Feb;41(1):30-41. Epub 2019 Jan 4 doi: 10.1007/s11096-018-0754-1. PMID: 30610548
Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
Yang Z, Hackshaw A, Feng Q, Fu X, Zhang Y, Mao C, Tang J
Int J Cancer 2017 Jun 15;140(12):2805-2819. Epub 2017 Mar 27 doi: 10.1002/ijc.30691. PMID: 28295308
Erlotinib for advanced hepatocellular carcinoma. A systematic review of phase II/III clinical trials.
Zhang J, Zong Y, Xu GZ, Xing K
Saudi Med J 2016 Nov;37(11):1184-1190. doi: 10.15537/smj.2016.11.16267. PMID: 27761555Free PMC Article

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Related information

    • ClinVar
      Related medical variations
    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...